Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Leiomyosarcoma × eribulin × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Sarcoma 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 Inflammatory Breast Neoplasms 1 HR Positive HER2 Negative Advanced Breast Cancer 1 HER-2 Positive Breast Cancer 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Brain Neoplasms 1

Interventions

Docetaxel 3 Trabectedin 2 temsirolimus 1 pazopanib 1 liposomal doxorubicin 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 eribulin 1 cemiplimab 1 avelumab 1 abemaciclib 1 Sunitinib 1 Specimen Handling 1 Radiotherapy 1 Nivolumab 1 Methotrexate 1 Ifosfamide 1 HhAntag691 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Dacarbazine 1 Cisplatin 1 Biopsy 1 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡